Dirk Westermann

Prof. Dirk Westermann

Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg 20246, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
Diana LindnerDiana Lindner
Diana Lindner
AFAntonia Fitzek
Antonia Fitzek
HBHanna Bräuninger
Hanna Bräuninger
GAGanna Aleshcheva
Ganna Aleshcheva
CECaroline Edler
Caroline Edler
DWDirk Westermann
Dirk Westermann
In patients with coronavirus disease 2019 (COVID-19), cardiovascular involvement occurs frequently. Myocardial injury with elevated troponin levels is described in patients hospitalized with COVID-191 and seems to be associated with outcome.2 The origin of myocardial injury can result from ischemia due to thrombotic coronary obstruction but can also include other causes such as heart failure, pulmonary embolism, tachycardia, and sepsis.3 Obviously, an infection of the myocardium with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is another alternative for elevated troponin. Next to elevated biomarkers for cardiac injury, myocardial dysfunction determined by echocardiography is also reported in up to 70% of hospitalized patients.4 This makes cardiac involvement during COVID-19, which manifests primarily as a pulmonary disease, likely.

1 December 2020 in Circulation
Verified
Journal Article
Open access
PDF file
BSBenedikt Schrage
Benedikt Schrage
PBPeter Moritz Becher
Peter Moritz Becher
ABAlexander Bernhardt
Alexander Bernhardt
HBHiram Bezerra
Hiram Bezerra
SBStefan Blankenberg
Stefan Blankenberg
DWDirk Westermann
Dirk Westermann
Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial recovery. The Impella unloads the left ventricle. This study aimed to evaluate whether left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO was associated with lower mortality. Methods: Data from 686 consecutive patients with cardiogenic shock treated with VA-ECMO with or without left ventricular unloading using an Impella at 16 tertiary care centers in 4 countries were collected. The association between left ventricular unloading and 30-day mortality was assessed by Cox regression models in a 1:1 propensity score–matched cohort. Results: Left ventricular unloading was used in 337 of the 686 patients (49%). After matching, 255 patients with left ventricular unloading were compared with 255 patients without left ventricular unloading. In the matched cohort, left ventricular unloading was associated with lower 30-day mortality (hazard ratio, 0.79 [95% CI, 0.63–0.98]; P =0.03) without differences in various subgroups. Complications occurred more frequently in patients with left ventricular unloading: severe bleeding in 98 (38.4%) versus 45 (17.9%), access site–related ischemia in 55 (21.6%) versus 31 (12.3%), abdominal compartment in 23 (9.4%) versus 9 (3.7%), and renal replacement therapy in 148 (58.5%) versus 99 (39.1%). Conclusions: In this international, multicenter cohort study, left ventricular unloading was associated with lower mortality in patients with cardiogenic shock treated with VA-ECMO, despite higher complication rates. These findings support use of left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO and call for further validation, ideally in a randomized, controlled trial.

6 October 2016 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
Federico PappalardoFederico Pappalardo
Federico Pappalardo
CSChristian Schulte
Christian Schulte
MPMarina Pieri
Marina Pieri
BSBenedikt Schrage
Benedikt Schrage
RCRachele Contri
Rachele Contri
DWDirk Westermann
Dirk Westermann

1 August 2018 in JACC
Verified
Journal Article
Closed access
RTRaphael Twerenbold
Raphael Twerenbold
JNJohannes Tobias Neumann
Johannes Tobias Neumann
NSNils Arne Sörensen
Nils Arne Sörensen
FOFrancisco Ojeda
Francisco Ojeda
MKMahir Karakas
Mahir Karakas
CMChristian Mueller
Christian Mueller

1 July 2016 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
JNJohannes Tobias Neumann
Johannes Tobias Neumann
NSNils Arne Sörensen
Nils Arne Sörensen
TSTjark Schwemer
Tjark Schwemer
FOFrancisco Ojeda
Francisco Ojeda
RBRafael Bourry
Rafael Bourry
DWDirk Westermann
Dirk Westermann
Early diagnosis of acute myocardial infarction (AMI) in patients presenting with acute chest pain improves clinical outcome. Moreover, rapid exclusion of AMI is important to triage patients in view of limited resources in the emergency department. Measurement of cardiac troponin levels, as a marker of myocyte necrosis, is essential for diagnosing AMI.1 Compared with sensitive troponin assays, high-sensitivity troponin assays enhance the accuracy and speed of the diagnosis,1-4 improve outcome, and are cost-effective.5

1 December 2018 in JACC: Heart Failure
Verified
Journal Article
Closed access
BSBenedikt Schrage
Benedikt Schrage
DBDaniel Burkhoff
Daniel Burkhoff
NRNicole Rübsamen
Nicole Rübsamen
PBPeter Moritz Becher
Peter Moritz Becher
MSMichael Schwarzl
Michael Schwarzl
DWDirk Westermann
Dirk Westermann